RxDoctor Payments Data

Mahesh Goel, MD

Urology · Carmel, INNPI 1205069762

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $881 of the $1,448 with a category attached, or 60.9%. Uromedica, Incorporated accounts for 60.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $881 and has fallen 98.1% since, to $17 in 2025. That places this record below the midpoint for urology clinicians in IN, where the typical reported total is $3,350.

$1,448in general payments, 2019–2025

Across 16 payments — averaging $90.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Uromedica, Incorporated$881
  • Axonics, Inc.$240
  • Endo Pharmaceuticals Inc.$172
  • Antares Pharma, Inc.$50
  • Astellas Pharma US Inc$43
  • 180 Medical, Inc.$29
  • plus $34 from 2 others

What the payments were for

  • Travel & lodging$88161%
  • Food & beverage$56739%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,448 in reported general payments places this provider in the 30th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana →

Medicare billing

Part B allowed, 2024
$135,323
Medicare patients
126
Services billed
1,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron24$13,660
Tolterodine Tartrate48$2,594
Tamsulosin Hcl191$2,264
Solifenacin Succinate33$1,071
Terazosin Hcl119$902
Oxybutynin Chloride41$686
Cephalexin61$542
NitrofurantoinNitrofurantoin Macrocrystal17$457
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$328
Ciprofloxacin Hcl46$298
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim36$224
Cefdinir15$140
Alendronate Sodium13$84
Hydrochlorothiazide15$51
Levofloxacin13$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$43$13,66024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 272 urology providers in Indiana.

Other urology in Carmel

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →